» Articles » PMID: 11921315

Is There a Kink in Consumers' Threshold Value for Cost-effectiveness in Health Care?

Overview
Journal Health Econ
Publisher Wiley
Date 2002 Mar 29
PMID 11921315
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A reproducible observation is that consumers' willingness-to-accept (WTA) monetary compensation to forgo a program is greater than their stated willingness-to-pay (WTP) for the same benefit. Several explanations exist, including the psychological principle that the utility of losses weighs heavier than gains. We sought to quantify the WTP-WTA disparity from published literature and explore implications for cost-effectiveness analysis accept-reject thresholds in the south-west quadrant of the cost-effectiveness plane (less effect, less cost).

Methods: We reviewed published studies (health and non-health) to estimate the ratio of WTA to WTP for the same program benefit for each study and to determine if WTA is consistently greater than WTP in the literature.

Results: WTA/WTP ratios were greater than unity for every study we reviewed. The ratios ranged from 3.2 to 89.4 for environmental studies (n=7), 1.9 to 6.4 for health care studies (n=2), 1.1 to 3.6 for safety studies (n=4) and 1.3 to 2.6 for experimental studies (n=7).

Conclusions: Given that WTA is greater than WTP based on individual preferences, should not societal preferences used to determine cost-effectiveness thresholds reflect this disparity? Current convention in cost-effectiveness analysis is that any given accept-rejection criterion (e.g. $50 k/QALY gained) is symmetric - a straight line through the origin of the cost-effectiveness plane. The WTA-WTP evidence suggests a downward 'kink' through the origin for the south-west quadrant, such that the 'selling price' of a QALY is greater than the 'buying price'. The possibility of 'kinky cost-effectiveness' decision rules and the size of the kink merits further exploration.

Citing Articles

Health Economic Evaluations of Circulating Tumor DNA Testing for Cancer Screening: Systematic Review.

Rui M, Wang Y, You J Cancer Med. 2025; 14(3):e70641.

PMID: 39907177 PMC: 11795416. DOI: 10.1002/cam4.70641.


Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program.

Kim D, Hwang J, Fendrick A Health Aff Sch. 2024; 2(6):qxae055.

PMID: 38828004 PMC: 11138958. DOI: 10.1093/haschl/qxae055.


Considering patient perspectives in economic evaluations of health interventions.

Fu R, Ng V, Liu M, Wells D, Yurga E, Nauenberg E Front Public Health. 2023; 11:1212583.

PMID: 37876714 PMC: 10593459. DOI: 10.3389/fpubh.2023.1212583.


Cost-effectiveness of monthly follow-up for the treatment of uncomplicated severe acute malnutrition: An economic evaluation of a randomized controlled trial.

Menzies N, Berthe F, Hitchings M, Aruna P, Hamza M, Nanama S PLOS Glob Public Health. 2023; 2(12):e0001189.

PMID: 36962786 PMC: 10022243. DOI: 10.1371/journal.pgph.0001189.


Cost-effectiveness of an educational intervention to reduce potentially inappropriate medication.

Rantsi M, Pitkala K, Kautiainen H, Hyttinen V, Kankaanpaa E Age Ageing. 2022; 51(5).

PMID: 35604803 PMC: 9126199. DOI: 10.1093/ageing/afac112.